MARATTO

article · Chinese Journal of Analytical Chemistry

Molecular docking, dynamic molecular simulation and in silico ADMET screening study of novel bidentate tetrazolyl-adipate anti-HIV drugs candidate

202510 citationsOpen accessUniversité Moulay Ismail de Meknes

Abstract

In order to develop specific inhibitors of CYP3A4, we chose new derivatives of adipic acid the 2,5-(5-aryl tetrazol-2yl) dimethyl adipate L 1 -L 5 . During this study, the Ritonavir molecule known as inhibitor of the cytochrome CYP3A4 are chosen as a reference. A molecular docking simulation on the enzyme 7UAZ is conducted for the ligands L 1 -L 5 , in order to study the predictive binding affinity and the interaction mechanism of the 5-aryltetrazolyl substituents introduced at positions 2 and 5 of adipic acid. A molecular docking study revealed that the relative activation energy level ranged from –10.1 to –7.6 kcal/mol, falling within the range of Ritonavir at –9.0 kcal/mol, which confirms the stability of the ligands within the studied enzyme. The results show that the binding mode of the ligands on the enzyme 7UAZ varies significantly depending on the substituent at the -C5 position of the tetrazole, with the best results obtained for the ligands L 2 and L 5 . Then a comparative study based on silico ADMET properties selected only L 2 as a potential inhibitor of CYP3A4. A 100 ns molecular dynamics simulation on the ligand-protein complex highlights the stability of ligand L 2 within the 7UAZ protein.

Research topics

  • Computational Drug Discovery Methods
  • Synthesis of Tetrazole Derivatives
  • Synthesis and biological activity

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1016/j.cjac.2025.100498

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.